Vitiligo during Treatment of Crohn's Disease with Adalimumab: Adverse Effect or Co-Occurrence

• Váldodahkkit: Celia Posada (Dahkki), Ángeles Flórez (Dahkki), Ana Batalla (Dahkki), Juan José Alcázar (Dahkki), Daniel Carpio (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Karger Publishers, 2011-02-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Adalimumab is a fully human monoclonal anti-tumor necrosis factor-α agent that is approved for the treatment of Crohn's disease. It has a good safety profile, injection site reactions being the most common adverse effect. We report a case of a 54-year-old woman with a 30-year history of Crohn&#...